ES2773105T3 - Forma cristalina de un inhibidor de transcriptasa inversa - Google Patents

Forma cristalina de un inhibidor de transcriptasa inversa Download PDF

Info

Publication number
ES2773105T3
ES2773105T3 ES13840379T ES13840379T ES2773105T3 ES 2773105 T3 ES2773105 T3 ES 2773105T3 ES 13840379 T ES13840379 T ES 13840379T ES 13840379 T ES13840379 T ES 13840379T ES 2773105 T3 ES2773105 T3 ES 2773105T3
Authority
ES
Spain
Prior art keywords
compound
range
oxo
methyl
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13840379T
Other languages
English (en)
Spanish (es)
Inventor
Courtney Maguire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2773105T3 publication Critical patent/ES2773105T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES13840379T 2012-09-26 2013-09-20 Forma cristalina de un inhibidor de transcriptasa inversa Active ES2773105T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705780P 2012-09-26 2012-09-26
PCT/US2013/060787 WO2014052171A1 (en) 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor

Publications (1)

Publication Number Publication Date
ES2773105T3 true ES2773105T3 (es) 2020-07-09

Family

ID=50388877

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13840379T Active ES2773105T3 (es) 2012-09-26 2013-09-20 Forma cristalina de un inhibidor de transcriptasa inversa

Country Status (9)

Country Link
US (1) US9150539B2 (OSRAM)
EP (1) EP2900240B1 (OSRAM)
JP (2) JP6387349B2 (OSRAM)
CN (2) CN109384765A (OSRAM)
BR (1) BR112015005997A8 (OSRAM)
CA (1) CA2882947A1 (OSRAM)
ES (1) ES2773105T3 (OSRAM)
MX (1) MX362517B (OSRAM)
WO (1) WO2014052171A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598397B2 (en) 2013-12-04 2017-03-21 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309700B2 (en) * 2004-04-02 2007-12-18 Boehringer Ingelheim International Gmbh Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one
CN1993332B (zh) * 2004-07-27 2011-04-06 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物
JP5341881B2 (ja) * 2007-05-30 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー トリアゾロン類の製造方法
MX2010005483A (es) * 2007-11-20 2010-06-11 Merck Sharp & Dohme Inhibidores de transcriptasa inversa no nucleosidos.
HUE031785T2 (en) * 2010-03-30 2017-08-28 Merck Canada Inc Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor
EP2558093A4 (en) * 2010-04-08 2013-10-02 Merck Sharp & Dohme PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR

Also Published As

Publication number Publication date
JP6387349B2 (ja) 2018-09-05
MX362517B (es) 2019-01-21
JP2015531372A (ja) 2015-11-02
WO2014052171A1 (en) 2014-04-03
BR112015005997A8 (pt) 2023-04-11
BR112015005997A2 (pt) 2017-07-04
CA2882947A1 (en) 2014-04-03
CN109384765A (zh) 2019-02-26
EP2900240B1 (en) 2020-01-08
CN104684557A (zh) 2015-06-03
EP2900240A1 (en) 2015-08-05
EP2900240A4 (en) 2016-07-13
US20150232447A1 (en) 2015-08-20
JP2018024683A (ja) 2018-02-15
US9150539B2 (en) 2015-10-06
MX2015003767A (es) 2015-07-14

Similar Documents

Publication Publication Date Title
DK1910370T3 (en) PYRIDINQUINOLINE SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR
AU2005222391B2 (en) HIV integrase inhibitors
CN110678178B (zh) Mk2抑制剂的形式和组合物
CA2965716C (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CN108026087B (zh) 氨基嘧啶甲酮衍生物的柠檬酸盐
CA3069038A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
ES2773105T3 (es) Forma cristalina de un inhibidor de transcriptasa inversa
AU2021277593A1 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
AU2019286641A1 (en) Small molecule inhibitors of the JAK family of kinases
IL280025B1 (en) A xinafoate salt of a jak inhibiting compound
CN112867708B (zh) 一种mdm2抑制剂，及其制备方法、药物组合物和应用
US20250019370A1 (en) L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof
KR20210012006A (ko) 5-((5-메틸-2-((3,4,5-트리메틸페닐)아미노)피리미딘-4-일)아미노)-벤조[d]옥사졸-2(3h)-온의 푸마레이트 염
ES2977643T3 (es) Proceso para fabricar inhibidores de la transcriptasa inversa
HK40062138B (zh) 一类2-氨基嘧啶类化合物及其药物组合物和用途
HK1259825B (en) Synthesis of indazoles
HK1259825A1 (en) Synthesis of indazoles